Pfizer (PFE) Free Cash Flow (2009 - 2026)

Pfizer has disclosed Free Cash Flow across 18 years of filings, most recently posting $2.2 billion for Q1 2026.

• In Q1 2026, Free Cash Flow rose 23.04% year-over-year to $2.2 billion; the TTM figure through Mar 2026 stood at $9.5 billion (up 180.23% YoY), while the FY2025 annual figure was $9.1 billion, down 7.73% from the prior year.
• Free Cash Flow eased to $2.2 billion in Q1 2026, from $4.5 billion in the prior quarter.
• Over the last five years, Free Cash Flow for PFE reached as high as $18.5 billion in Q4 2022 and fell as low as -$2.4 billion in Q2 2024.
• The 5-year median for Free Cash Flow is $2.6 billion (2023), against an average of $3.3 billion.
• Annual changes were most pronounced in 2023 — Free Cash Flow tumbled 128.6% — and 2024, when it surged 428.77%.
• A 5-year view of Free Cash Flow shows it stood at $18.5 billion in 2022, then sank by 77.26% to $4.2 billion in 2023, then dropped by 3.93% to $4.0 billion in 2024, then climbed by 11.71% to $4.5 billion in 2025, then plunged by 51.61% to $2.2 billion in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered $2.2 billion, $4.5 billion, and $4.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.